Cardiac cachexia and muscle wasting: definition, physiopathology, and clinical consequences

Abstract: Cachexia and muscle wasting are frequently observed in heart failure patients. Cachexia is a predictor of reduced survival, independent of important parameters such as age, heart failure functional class, and functional capacity. Muscle and fat wasting can also predict adverse outcome during cardiac failure. Only more recently were these conditions defined in International Consensus. Considering that heart failure is an inflammatory disease, cardiac cachexia has been diagnosed by finding a body weight loss >5%, in the absence of other diseases and independent of other criteria. Muscle wasting has been defined as lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean for healthy individuals between 20 years and 30 years old from the same ethnic group. The etiology of heart failure-associated cachexia and muscle wasting is multifactorial, and the underlying physiopathological mechanisms are not completely understood. The most important factors are reduced food intake, gastrointestinal alterations, immunological activation, neurohormonal abnormalities, and an imbalance between anabolic and catabolic processes. Cachexia and muscle wasting have clinical consequences in several organs and systems including the gastrointestinal and erythropoietic systems, and the heart, previously affected by the primary disease. We hope that a better understanding of the mechanisms involved in their physiopathology will allow the development of pharmacological and nonpharmacological therapies to effectively prevent and treat heart failure-induced cachexia and muscle wasting before significant body weight and muscle wasting occurs.

Keywords: heart failure, prognosis, anorexia, inflammatory activation, cardiac wasting

Introduction
Heart failure is a complex clinical syndrome in which damage to the heart or increased myocardial stress activates a systemic response that adversely affects cardiac structures and function over time.¹ In the past few decades with a better understanding of heart failure physiopathology, it has become clear that pathological changes not only involve the cardiovascular system but also the renal, neuroendocrine, immune, musculoskeletal, hematological, and gastrointestinal systems, as well as nutritional state. Several studies have been performed to elucidate the physiopathology of systemic complications in heart failure and establish therapeutic measures to improve quality of life and increase survival. These include studies on heart failure-associated cachexia and muscle wasting. In this review, we present a definition, the physiopathology, and clinical consequences of cardiac cachexia and muscle wasting.

Cachexia is a strong predictive factor for reduced survival in heart failure, independent of important variables such as age, functional class, ejection fraction, and...
The importance of cachexia in prognosis was reinforced after the description of reverse epidemiology of obesity in heart failure. In healthy individuals, increased body mass index is associated with an increased risk of developing cardiovascular disease. However, body mass index positively correlates with survival in heart failure patients.\footnote{Oreopoulos et al\textsuperscript{3} established that mortality rates from all causes and cardiovascular disease are reduced in overweight and obese heart failure patients.} In a large meta-analysis of nine observational studies, Oreopoulos et al\textsuperscript{3} established that mortality rates from all causes and cardiovascular disease are reduced in overweight and obese heart failure patients. The mechanisms responsible for this obesity paradox in heart failure are not completely clear.\footnote{As for cachexia, muscle wasting has been recently associated with parameters that indicate poor prognosis, such as reduced exercise capacity, muscle strength, and total peak oxygen consumption. Despite being known for a long time that severe body weight loss is associated with poor outcomes in several diseases, the mechanisms responsible for cachexia-induced death are not completely clear.}

\section*{Definition of cachexia and muscle wasting}

Although cachexia is characterized by body weight loss and muscle wasting by a reduction in muscle mass without body weight loss,\footnote{Definition of these terms has evolved over time. The term “cachexia” originates from the Greek and means “bad condition”. Some patients present with such intense body weight loss that cachexia diagnosis is plainly evident. However, it is often difficult to diagnose cachexia in heart failure patients, as edema increases body weight and interferes with the evaluation of other anthropometric measurements. Furthermore, it may be difficult to interpret results from nutritional biomarkers and estimate body composition through bioelectrical impedance analysis, particularly when body water is increased.} definition of these terms has evolved over time. The term “cachexia” originates from the Greek and means “bad condition”. Some patients present with such intense body weight loss that cachexia diagnosis is plainly evident. However, it is often difficult to diagnose cachexia in heart failure patients, as edema increases body weight and interferes with the evaluation of other anthropometric measurements. Furthermore, it may be difficult to interpret results from nutritional biomarkers and estimate body composition through bioelectrical impedance analysis, particularly when body water is increased.\footnote{Due to its influence on heart failure prognosis, it is important to have a specific simple definition of cachexia so that physicians can easily recognize the problem. However, cardiac cachexia has already had different definitions. In 1997, Anker et al\textsuperscript{14} proposed that, in heart failure patients, cachexia should be diagnosed when non-intentional edema-free body weight loss was \(>7.5\%\) of usual weight in the absence of hyperthyroidism or neoplastic and infectious diseases. Body weight loss should have occurred in a period longer than 6 months. Weight loss in shorter periods can also be due to heart failure, but other causes such as neoplastic or infectious diseases should be investigated. Later, the same authors observed that less intense body weight loss is already associated to worsening prognosis and proposed that a \(6\%\) body weight loss should be enough to characterize cardiac cachexia. In 2006, during the Cachexia Consensus Conference, cachexia was defined as at least \(5\%\) edema-free body weight loss in the previous 12 months (or a body mass index <20 kg/m\(^2\)) in patients with chronic illness and at least three of the following clinical or laboratory criteria: decreased muscle strength, fatigue, anorexia, low fat-free mass index, and abnormal biochemistry characterized by increased inflammatory markers (C-reactive protein, interleukin [IL]-6), anemia (Hb <12 g/dL), or low serum albumin (<3.2 g/dL). It should be pointed out that cachexia differs from malnutrition or anorexia, conditions that differently from cachexia can easily be reversed with adequate nutrition. As heart failure is considered an inflammatory disease, cardiac cachexia has been diagnosed when body weight loss is \(>5\%\) independent of other criteria.}

Body weight loss leads to skeletal muscle loss and vice versa. However, isolated skeletal muscle loss can also be observed during heart failure. Chronic disease-associated muscle loss has been preferably called muscle wasting as the term “sarcopenia” usually refers to healthy age-related muscle loss.\footnote{Differently from cachexia, muscle-wasting diagnosis depends on laboratory investigation. Dual-energy X-ray absorptiometry has been used to accurately evaluate body composition and estimate total, lean, and fat mass. However, although expensive, computed tomography, and magnetic resonance imaging are the gold standard for muscle mass assessment. The definition of muscle wasting has recently been established as lean appendicular mass corrected for height squared of 2 or more standard deviations below the mean of healthy persons between 20 years and 30 years of age of the same ethnic group. Muscle wasting can also be suggested by a poor physical performance observed in different evaluation methods such as a 6-minute walk, handgrip strength, gait speed, or spiroergometry.} Body weight loss leads to skeletal muscle loss and vice versa. However, isolated skeletal muscle loss can also be observed during heart failure. Chronic disease-associated muscle loss has been preferably called muscle wasting as the term “sarcopenia” usually refers to healthy age-related muscle loss.\footnote{Differently from cachexia, muscle-wasting diagnosis depends on laboratory investigation. Dual-energy X-ray absorptiometry has been used to accurately evaluate body composition and estimate total, lean, and fat mass. However, although expensive, computed tomography, and magnetic resonance imaging are the gold standard for muscle mass assessment. The definition of muscle wasting has recently been established as lean appendicular mass corrected for height squared of 2 or more standard deviations below the mean of healthy persons between 20 years and 30 years of age of the same ethnic group. Muscle wasting can also be suggested by a poor physical performance observed in different evaluation methods such as a 6-minute walk, handgrip strength, gait speed, or spiroergometry.}

\section*{Epidemiology}

By defining cachexia as a body weight loss \(\geq 6\%\), Anker et al\textsuperscript{15} observed that \(34\%\) of heart failure outpatients developed cachexia during 48 months of follow-up. Post hoc analyses of several heart failure trials have reported a prevalence of edema-free weight loss ranging from \(8\%\) to \(42\%\).\footnote{More recently, in optimally treated nondiabetic outpatients, cachexia (body weight loss \(>5\%\)) was observed in \(10.5\%\). Muscle-wasting prevalence has received less characterization in literature. Using the definition of muscle wasting}
mentioned earlier, this condition was recently observed in 19.5% of patients with stable chronic heart failure.8

**Physiopathology of heart failure-induced cachexia**

The etiology of heart failure-associated cachexia and muscle wasting is multifactorial, and the underlying physiopathological mechanisms are not completely understood. Although these mechanisms can differentially affect cachexia and muscle wasting, we present here the main factors responsible for the development of both conditions.

**Imbalance between anabolic and catabolic processes**

Skeletal muscle abnormalities are well established in heart failure and contribute to early dyspnea and fatigue during physical activity.21–23 Maintenance of skeletal muscle mass depends on a delicate balance between anabolic and catabolic factors. Anabolic and catabolic process imbalance has gained increasing importance in the physiopathology of heart failure-induced cachexia and muscle wasting.24,25 Enhanced proteolysis is the most consistent finding, whereas there is limited evidence for reduced protein synthesis.26 The following major proteolytic pathways can be found in skeletal muscle: lysosomal, Ca2+-dependent, caspase dependent, and ubiquitin–proteasome dependent.27 One of the most important pathways responsible for intracellular degradation of striated muscle proteins is the ubiquitin–proteasome system.28–30 During ubiquitination, damaged cytosolic proteins are linked to ubiquitin molecules and targeted toward the proteasome, where they are cleaved into short peptides and aminoacids.31

In heart failure, immunological and neurohormonal activation, as well as increased reactive oxygen species levels, stimulate nuclear factor-xB, which activates the ubiquitin proteasome system.13,27 In fact, components of the ubiquitin–proteasome system such as the muscle-specific E3 ligase muscle ring finger 1 were shown to be stimulated by proinflammatory cytokines and increased in skeletal muscle during heart failure.13,31 The ubiquitin–proteasome system can also be stimulated by myostatin and inhibited by follistatin. Myostatin modulates muscle growth by acting as a negative regulator of muscle bulk, and follistatin is a potent antagonist of myostatin. During pathological loading of the heart, the myocardium produces and secretes myostatin into circulation where it reaches skeletal muscles and inhibits their growth.32 We have observed in heart failure rats that muscle atrophy was combined with changes in myostatin/follistatin expression.22,33 Muscle disuse by bed rest can also contribute to protein catabolism.26

The most important consequence of increased protein degradation is a reduction in myocyte cross-sectional area and muscle mass, which contributes to a reduction in physical performance and daily living activities.21,34–38 As well as by increased proteolysis, reduced muscle mass can also be caused by apoptosis or necrosis.35,38,39 During several pathological conditions, muscle loss is not homogeneous and can involve predominantly slow type 1 or fast type 2 muscle fibers.40 Also in heart failure, muscle loss pattern depends on experimental model, and both a slow-to-fast and a fast-to-slow fiber-type shift has been described.33,41

Recently, Callahan and Toth26 suggested that increased proteolysis and reduced protein synthesis mainly occur during disease exacerbation and hospitalization due to increased inflammatory and neurohormonal activation. As anabolic pathways are probably insufficient to recover muscle size and function to prehospitalization levels, efforts to prevent disease exacerbation should be emphasized.26

Finally, it has been showed that increased catabolism not only occurs in skeletal muscle but also in adipose tissue.52,43

**Neurohormonal alterations**

During cardiac failure, neurohormonal activation is related to several deleterious cardiac and systemic effects. Heart failure patients with cachexia present increased plasma concentrations of noradrenaline, epinephrine, cortisol, and aldosterone than healthy individuals or heart failure patients without cachexia, suggesting that systemic neurohormonal activation is involved in the physiopathology of cachexia.2,3 Clinical trials have shown that angiotensin-converting enzyme inhibitors and β-blockers reduce the probability of weight loss. In in vitro studies, angiotensin II (AII), aldosterone, and catecholamines induce inflammatory cell activation and cytokine synthesis.45–47 Adrenergic stimulation may increase resting energy expenditure and induce vasoconstriction, impairing intestinal perfusion and bacterial translocation.27,48 Experimental studies have shown that AII can contribute to muscle wasting by increasing protein breakdown, reducing protein synthesis, and inhibiting muscle regenerative processes.28,49

More recently, the role of neurohormonal activation has also been evaluated in noncardiac cachexia. In liver cancer rats, β-blocker or aldosterone antagonism has increased survival and improved cancer-induced cardiac dysfunction.50

Other hormonal changes can also be involved in cachexia and muscle wasting. Heart failure patients can present a
state of growth hormone resistance. As a consequence, insulin growth factor (IGF)-1, which stimulates protein synthesis, myoblast differentiation, and muscle growth, is decreased.\textsuperscript{31–33} IGF-1 levels can also be downregulated by AII stimulation.\textsuperscript{27} IGF-1, in turn, prevents AII-induced skeletal muscle wasting through an Akt/forkhead box O–dependent pathway.\textsuperscript{54} N-terminal fragment levels of prohormone brain-type natriuretic peptide (NT-proBNP), usually increased in decompensated patients, are inversely correlated with abdominal fat, suggesting that this hormone may be involved in abdominal lipolysis.\textsuperscript{17,43}

**Immunological activation**

After the first report by Levine et al\textsuperscript{55} in 1990, showing that heart failure patients present increased tumor necrosis factor (TNF)-\(\alpha\) serum levels, cardiac failure was considered as an immunologically activated disease. It was later verified in large trials such as SOLVD\textsuperscript{56} and VEST\textsuperscript{57} that TNF-\(\alpha\) serum concentration is a good predictor of functional class, cardiac performance, and survival. These results were very important in understanding the physiopathology and systemic complications of heart failure. As well as TNF-\(\alpha\), other inflammatory cytokines such as IL-6, the IL-1 family, and anti-inflammatory cytokines such as IL-10 are also changed in heart failure.\textsuperscript{27,58}

Several cells can secrete cytokines. During heart failure, the injured myocardium and skeletal myocytes can produce and release cytokines into the circulation.\textsuperscript{27} Cytokine synthesis can be stimulated by several factors including hemodynamic overload, neurohormonal activation, tissue hypoxemia and hypoperfusion, and, as previously reported, endotoxin-like lipopolysaccharides.\textsuperscript{58} In experimental studies, increased TNF-\(\alpha\) expression induces several deleterious effects; these include heart failure phenotype, endothelial dysfunction, erythropoiesis inhibition, gut permeability change, decreased free radical enzyme-removing activity, cachexia, and skeletal muscle changes such as apoptosis, proteolysis, atrophy, and functional alterations in contractile proteins.\textsuperscript{59–61} Inflammatory cytokine-induced skeletal muscle changes have important consequences on inducing muscle wasting and cachexia.

**Gastrointestinal abnormalities**

The role of gastrointestinal system on cardiac cachexia has recently been studied in detail.\textsuperscript{62} Several structural changes have been described such as collagen accumulation and increased thickness of the intestine wall, which suggest bowel wall edema.\textsuperscript{63,64} These alterations increase the distance between capillary wall and enterocyte membrane and can impair both intestinal mucosa perfusion and gut absorption.\textsuperscript{55} Functional changes such as reduced protein and fat absorption and increased paracellular passive permeability have also been described.\textsuperscript{65,66} Additionally, increased bacteria concentration and the extent of their adherence to sigmoidal mucosal biofilm have been observed in heart failure.\textsuperscript{67} The combination of increased paracellular permeability and intestinal bacteria colonization can contribute to an increase in the gut permeability to bacterial endotoxin-like lipopolysaccharides.\textsuperscript{51} This process is known as bacterial translocation. Lipopolysaccharides are considered powerful inducers of TNF-\(\alpha\) and other proinflammatory substances.\textsuperscript{27,59,66} Finally, as hepatic abnormalities in heart failure are relatively common, they can impair the removal of bacterial endotoxins, thus contributing to immune activation.\textsuperscript{68} All these data strongly suggest that heart failure-induced gastrointestinal abnormalities are involved in systemic inflammatory activation, cachexia, and muscle wasting.

**Food intake reduction**

Reduced food intake can be caused by anorexia, whose causal mechanisms are not completely clear. Several factors may be involved such as poor diet palatability due to low sodium content, severe depression, and passive visceral congestion. Drugs often used in treating heart failure can contribute to reduce food intake. Angiotensin-converting enzyme inhibitors, particularly captopril, can change food taste and reduce food intake. Digitalis intoxication usually causes anorexia, nausea, and vomiting.\textsuperscript{51} Chronic and vigorous use of diuretics can deplete body potassium, reducing intestinal motility, and zinc, changing food palatability.\textsuperscript{64} Inflammatory cytokine activation and abnormal leptin and adiponectin serum levels also cause anorexia.\textsuperscript{68}

Heart failure patients also experience intrinsic disturbances in appetite regulation. The hypothalamus is the main site-regulating appetite. Several neuropeptides act on different areas of the hypothalamus inducing appetite or satiety. It has been suggested in heart failure that satiety-inducing neuropeptides predominate over those leading to hunger and appetite.\textsuperscript{69} In fact, it was recently showed in mice that AII decreases food intake by suppressing hypothalamic expression of orexigenic neuropeptides.\textsuperscript{70}

Other factors besides anorexia can also contribute to reduced food intake, including early satiety due to severe hepatomegaly, and reduced lipid intake, which is frequently recommended for coronary artery disease patients. A decrease in this dietary nutrient, which has a high energetic density,
may not be compensated for by a proportional increase in carbohydrate intake. Finally, it should be pointed out that, in functional class IV patients, resting dyspnea is a limiting factor for food intake.

Finally, an increase in resting energy expenditure seems not to be involved in body weight loss during heart failure. Recent studies have shown that cachectic patients do not present with significantly increased resting energy expenditure compared with noncachectic patients and healthy controls. 

Clinical consequences of cachexia

The clinical manifestations of cachexia are caused by both weight loss and systemic inflammation. In cachexia, there is a loss of tissue from three compartments: lean tissue, fat mass, and bones. As can be seen from the previous section, skeletal muscle wasting can be both a cause or a consequence of cachexia. Increased catabolism and body weight loss are also associated with a decrease in respiratory muscle strength.

It was recently observed that fat mass wasting is also predictive of adverse outcome. It is not known whether fat loss is a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the heart failure context.

Severe body weight loss, even in the absence of systemic inflammation, is associated with deleterious effects in most organs and systems, including changes in cardiac and gastrointestinal systems, anemia, reduced immunity, an increased risk of acquiring infections, alterations in respiratory function, reduced bone and muscle mass, decreased capacity to urinary concentration and acidification, reduced tissue healing, and a predisposition to pressure ulcers in bed rest patients.

It is not possible to determine the cardiac consequences of heart failure-induced cachexia as the heart is primarily affected. Experimental studies have shown that cancer cachexia induces left ventricular dysfunction and molecular changes characteristic of the pathologic remodeling process. In our laboratory, we evaluated the cardiac effects of severe food restriction in normotensive and hypertensive rats. Body weight reduction was associated with a reduction in heart mass. In normotensive animals, morphological, ultrastructural, and functional myocardial changes were slight. However, in the hypertrophied heart of hypertensive rats, structural changes were more severe and were combined with ventricular and myocardial systolic dysfunction. Therefore, severe food restriction induces mild morphological and functional changes in normal hearts, which are exacerbated in hemodynamic overloaded hearts. In clinical setting, it was recently observed that left ventricular mass correlates with lean body mass in cachectic patients showing that the heart suffers similar consequences than lean tissue during cachexia.

Cachexia can exacerbate heart failure-associated gastrointestinal changes by inducing enterocyte atrophy, reducing gut villi, and increasing the risk of bacterial translocation.

Finally, anemia, a frequent complication of heart failure, can also be impaired by cachexia. Although anemia etiology is multifactorial, cachexia-related factors such as reduced intestinal absorption and chronic inflammation contribute to its physiopathology. Iron deficiency has been reported in variable frequency during heart failure ranging from 1% to 44%, depending on case severity. Iron deficiency not only impairs erythropoiesis but also dilates the left ventricle, induces cardiac ultrastructural and mitochondrial changes, impairs cardiac function, stimulates the sympathetic nervous system, causes thrombocytosis, and impairs quality of life.

Treatment perspectives

The multifactorial pathogenesis of these conditions has complicated the development of specific therapy for heart failure-induced cachexia and muscle wasting. Different treatment options have been described, mostly evaluated only in experimental settings or in small clinical studies. Currently, nonpharmacological therapy as nutritional support and physical exercise is considered the basis for treating these conditions. It is important to point out that an increase in food intake may compensate some weight loss, but it can cause a shift in tissue distribution, particularly when muscle loss is present. Therefore, nutritional support should be combined with exercise training in order to preserve or recover muscle mass. In fact, exercise training has been considered the most promising option for treating muscle wasting in several diseases. Table 1 shows a schematic description of potential therapeutic options for patients with cardiac cachexia and muscle wasting.

In conclusion, cardiac-associated cachexia and muscle wasting are multifactorial conditions that contribute to increased morbidity and mortality in heart failure. A better understanding of the mechanisms involved in their physiopathology will hopefully lead to the development of pharmacological and nonpharmacological therapies to effectively prevent and treat heart failure-induced cachexia and muscle wasting before significant body weight and muscle wasting occurs.
Appetite Stimulants
ACE inhibitors
Prevention of weight loss
Anabolic steroids
TNF-β
Anti-inflammatory substances
Medroxyprogesterone acetate

Table 1 Potential clinical and experimental therapeutic approaches to counteract cardiac cachexia and muscle wasting

<table>
<thead>
<tr>
<th>Nonpharmacological approaches</th>
<th>Pharmacotherapy of cardiac cachexia</th>
<th>Drug therapy</th>
<th>Prevention of weight loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrition Exercise</td>
<td>Anti-inflammatory substances</td>
<td>Appetite Stimulants</td>
<td>ACE inhibitors</td>
</tr>
<tr>
<td></td>
<td>TNF-α inhibitory antibodies</td>
<td>Megestrol acetate</td>
<td>β-Blockers</td>
</tr>
<tr>
<td></td>
<td>Inhibition of lipopolysaccharide bioactivity</td>
<td>Medroxyprogesterone acetate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Statins</td>
<td>Cannabinoids</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thalidomide</td>
<td>Anabolic steroids</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proteasome inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other substances (pentoxifylline)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Acknowledgments
The authors thank FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) (Proc No 2012/21687-1 and 2012/50512-5), CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico), and UNESP (Universidade do Estado de Sao Paulo) for financial support.

Disclosure
The authors report no conflicts of interest in this work.

References


